HER2/neu-directed therapy for biliary tract cancer

Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway

(2014) Maolan Li et al.   NATURE GENETICS

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

(2013) Vikram Deshpande et al.   BMC CANCER

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

(2013) Yaohui Wang et al.   CURRENT MEDICAL RESEARCH AND OPINION

HER2-positive gastric cancer

(2013) Narikazu Boku   Gastric Cancer

Molecular characterization of gallbladder cancer using somatic mutation profiling

(2013) Milind Javle et al.   HUMAN PATHOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics

(2013) Rashmi Kanagal-Shamanna et al.   MODERN PATHOLOGY

HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

(2013) Diana P. English et al.   Molecular Diagnosis & Therapy

Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer

(2012) M. Terashima et al.   CLINICAL CANCER RESEARCH

Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Cholangiocarcinoma

(2012) Lisa Y. Law   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

(2012) H. Wong et al.   ONCOLOGIST

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Whole Cancer Genome Sequencing by Next-Generation Methods

(2011) Jeffrey S. Ross et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011

(2011) Frédérique Penault-Llorca et al.   ANNALES DE PATHOLOGIE

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

(2011) Koichi Azuma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review

(2011) Terence C. Chua et al.   INTERNATIONAL JOURNAL OF CANCER

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

(2010) Xiaohong R. Yang et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder

(2009) Nafis Shafizadeh et al.   HUMAN PATHOLOGY

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

(2009) Andreas Gnirke et al.   NATURE BIOTECHNOLOGY